Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • Data Privacy
  • Français
  • my CNW 
    • Login
    • Register
  • Client Login 
    • Online Member Centre
    • Next Gen Communications Cloud
    • Cision Communications Cloud®
  • Sign Up
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
Advanced Search
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Canadian Federal Government
      • Canadian Municipal Government
      • Canadian Provincial Government
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

  • Advanced Search
  • Overview
  • Multichannel Amplification
  • Monitoring
  • Distribution
  • Multimedia
  • Guaranteed Paid Placement
  • AI Tools
  • IR
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Worldwide Offices
  • Hamburger menu
  • Cision Canada
  • Send a Release
  • FR
    • Phone

    • 877-269-7890 from 8 AM - 10 PM ET

    • ALL CONTACT INFO
    • Contact Cision

      877-269-7890
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • Overview
  • Multichannel Amplification
  • Monitoring
  • Distribution
  • Multimedia
  • Guaranteed Paid Placement
  • AI Tools
  • IR
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR

When Bedtime Insulin Is Not Enough; Why Wait? Français


News provided by

Novo Nordisk Canada Inc.

Jan 25, 2012, 09:00 ET

Share this article

Share toX

Share this article

Share toX

Speed
Speed
Quality
Quality
View PDF

With simple changes, effective management of type 2 diabetes can help prevent secondary complications

TORONTO, Jan. 25, 2012 /CNW/ - Half of Canadians with type 2 diabetes are not properly managing their disease - the majority of whom are at risk for health conditions linked to diabetes like blindness,  heart disease or kidney disease.1,2 In many cases, insulin therapy is required to improve diabetes control.  This begs the question: why wait when it comes to stepping up to insulin as an effective diabetes management strategy?

Type 2 diabetes is a progressive, life-long condition, and effective management of the disease is essential and unique to each individual. 3,4

In Canada, the guidelines for type 2 diabetes highlight the importance of reaching blood sugar targets.  The recommended treatment timeline suggests getting to the target blood sugar level (A1c of less than or equal to 7.0%) within 6-12 months.5  Insulin is often a key treatment option to help reach the target as highlighted in the recommendations.5

However, a recent Canadian study found that in reality, it took an average of 9.2 years before insulin therapy was started and 75 per cent of patients were still not at target approximately one year afterwards.6 Addressing the barriers to insulin therapy is essential as clinical inertia, or an inadequate increase of insulin therapy, can result in many patients being unable to achieve and sustain glycemic control; essentially putting them at risk for developing serious complications.6  Although target levels can often be achieved with bedtime (basal) insulin, adding mealtime insulin is sometimes needed to get blood sugar levels to target levels.7

According to a recent STEPwise™ study, adding mealtime insulin for people with type 2 diabetes does not have to be complicated.  In fact, mealtime insulin added in a simple way, starting with one meal at a time, is a safe and effective practice to help patients reach target levels.8

Individuals living with type 2 diabetes should speak to their doctor or other healthcare professional about effective diabetes management strategies, including insulin, and the need to increase treatment to keep blood sugar levels within their target range.  Why wait?

Type 2 Diabetes:

  • Occurs when the pancreas does not produce enough insulin to meet the body's needs and/or the body is unable to respond properly to the actions of insulin (insulin resistance).1
  • Accounts for 90 per cent of all cases of diabetes in Canada.1
  • Is being diagnosed at younger and younger ages; though the mean age of diagnosis is 40+ years of age.6
  • Is treated with diabetes medications (antihyperglycemic agents) and/or insulin, which are often coupled with careful attention to diet and exercise.1

Quotes
"It's important that the barriers to insulin intensification are recognized and accommodated, as a delay in adding an additional intake of insulin for a person living with type 2 diabetes can lead to serious complications that can otherwise be avoided."

                      Dr. Stewart Harris, Professor, Centre for Studies in Family Medicine, Schulich School of Medicine & Dentistry, The University of Western Ontario, CDA Chair in Diabetes Management, Ian McWhinney Chair of Family Medicine Studies

Boilerplate
Novo Nordisk is a healthcare company and a world leader in diabetes care and biopharmaceuticals.  Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society.  Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to economic success, environmental soundness, and social responsibility to employees and customers. For more information, visit www.novonordisk.ca.

References
_____________________________
1 Canadian Diabetes Association.  Diabetes in Canada: Canada at the Tipping Point - Charting a New Path.  http://www.diabetes.ca/documents/get-involved/WEB_Eng.CDA_Report_.pdf. Accessed August 2011.
2 Canadian Diabetes Association. Diabetes and You. Complications. http://www.diabetes.ca/diabetes-and-you/living/complications/. Accessed August 2011.
3 Canadian Diabetes Association.  Type 2 Diabetes: The Basics.  http://www.diabetes.ca/diabetes-and-you/living/just-diagnosed/type2/.  Accessed August 2011.
4 Canadian Diabetes Association.  Diabetes Current: Medical Conditions Do Not Define Patients.  http://www.diabetes.ca/current/edition/2011/02/.  Accessed August 2011.
5 Canadian Diabetes Association.  Canadian Journal of Diabetes: Canadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada.  September 2008, Vol.32, Supplement 1.  http://www.diabetes.ca/files/cpg2008/cpg-2008.pdf.  Accessed September 2011.
6 Harris, S., et al.  Clinical inertia in patients with T2DM requiring insulin in family practice.  Canadian Family Physician.  Vol. 56; 418-424.  December 2010.
7 Holman, R, Thorne K, Farmer, A, et al. Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes.  N Engl J Med 2007; 357.  Published online: September 21, 2011.
8 Meneghini L, Mersebach H, Kumar S, et al. A comparison of two intensification regimens with rapid-acting insulin aspart in type 2 diabetes inadequately controlled by once-daily insulin detemir and oral antidiabetes drugs: the STEP-Wise™ randomized study. Endocr Pract. Published online: May 6, 2011.
9 Public Health Agency of Canada.  Type 2 Diabetes Info Sheet for Seniors.  http://www.phac-aspc.gc.ca/seniors-aines/publications/public/age/info/type2-diabetes/index-eng.php.  Accessed November 2011.

 

 

Video with caption: "Video: When Bedtime Insulin Is Not Enough; Why Wait?". Video available at: http://stream1.newswire.ca/cgi-bin/playback.cgi?file=20120125_C6197_VIDEO_EN_9121.mp4&posterurl=http://photos.newswire.ca/images/20120125_C6197_PHOTO_EN_9121.jpg&clientName=Novo%20Nordisk%20Canada%20Inc%2E&caption=Video%3A%20When%20Bedtime%20Insulin%20Is%20Not%20Enough%3B%20Why%20Wait%3F&title=When%20Bedtime%20Insulin%20Is%20Not%20Enough%3B%20Why%20Wait%3F&headline=When%20Bedtime%20Insulin%20Is%20Not%20Enough%3B%20Why%20Wait%3F

PDF with caption: "Why Wait Diabetes Backgrounder". PDF available at: http://stream1.newswire.ca/media/2012/01/25/20120125_C6197_DOC_EN_9148.pdf

Jacqueline Zonneville
NATIONAL Public Relations
416-848-1398
[email protected]

Jeremy Brace
Novo Nordisk Canada Inc.
905-629-6241
[email protected]

Modal title

Organization Profile

Novo Nordisk Canada Inc.

    Also from this source

  • CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in NEJM

  • Higher dose of semaglutide provided average weight loss of 21% in people with obesity - with a third achieving 25% or more - according to data presented at ADA

  • Health Canada accepts semaglutide 2.4 mg, a GLP-1RA treatment for MASH, as a supplemental New Drug Submission under the Priority Review Policy

Contact Cision

  • 866-245-2317
    from 8 AM - 10 PM ET
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media

Products

  • Cision Communications Cloud®
  • Media Monitoring
  • Content Distribution
  • Multimedia Distribution
  • Measurement & Analytics
  • Investor Relations

About

  • About Cision Canada
  • About Cision
  • Media Partners
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Online Member Centre
  • Next Gen Communications Cloud
  • Cision Communications Cloud®
  • my CNW

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Centre
  • Next Gen Communications Cloud
  • Cision Communications Cloud
  • my CNW
877-269-7890
from 8 AM - 10 PM ET
  • Terms of Use
  • Information Security Policy
  • Site Map
  • Cookie Settings
  • Accessibility Statement
Copyright © 2025 CNW Group Ltd. All Rights Reserved. A Cision company.